Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1

• Published in: Thyroid research 2013-08, Vol.6 (1), p.9-9
• Main Authors: Lewinski, Andrzej, Brona, Anna, Lewandowski, Krzysztof C, Jedrzejuk, Diana, Bohdanowicz-Pawlak, Anna, Skowronska-Jozwiak, Elżbieta, Bienkiewicz, Małgorzata, Milewicz, Andrzej
• Format: Article
• Language: English
• Subjects: Acquisitions & mergers; Adverse and side effects; Cardiovascular disease; Care and treatment; Colleges & universities; Diabetes; Drugs; Evaluation; Hyperthyroidism; Hypothyroidism; Iodine; Isotopes; Measurement; Medical research; Medicine, Experimental; Metabolic disorders; Mortality; Patient outcomes; Proteases; Statistical analysis; Thyroid diseases; Type 2 diabetes
• ISSN: 1756-6614; 1756-6614
• DOI: 10.1186/1756-6614-6-9

In order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor - TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor - TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1). The study involved 23 patients treated with radioiodine for thyrotoxicosis. Serum concentrations of TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured by immunoassays just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), 6 to 8 months (visit 4) and 15-18 months after radioiodine administration (visit 5). There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 (visit 1 vs. 2). Subsequently, there was an increase in MMP-2 (from 393±106 ng/ml to 774±424 ng/ml), TIMP-1 (from 177±76 ng/ml to 296±118 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to 5, respectively (p